Skip to main content

Table 2 Vemurafenib pharmacokinetics in the pharmacokinetic cohort

From: Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

   Vemurafenib (N = 20)
Study day Parameter Mean ± SD CV %
Day 1 AUC0-8h, μg·h/mL 37.5 ± 22.3 59.4
AUC0-12h, μg·h/mL 57.5 ± 32.6 56.7
Cmax, μg/mL 6.9 ± 3.9 55.8
Day 15 Ctrough, μg/mL 63.0 ± 23.3 37.0
Day 21 AUC0-8h, μg·h/mL 501.3 ± 123.0 24.5
AUC0-12h, μg·h/mL 720.3 ± 185.8 25.8
Cmax, μg/mL 77.6 ± 17.9 23.0
Ctrough, μg/mL 72.6 ± 20.0 27.5
t½, h 35.6 ± 18.1
Accumulation ratio 17.9 ± 14.1
  1. SD standard deviation, CV coefficient of variation, AUC 0-8h area under the concentration-time curve from 0 to 8 h, AUC 0-12h area under the concentration-time curve from 0 to 12 h, C max maximal plasma concentration, C trough plasma trough concentration, t ½ terminal half-life, accumulation ratio AUC0-8h on day 21/AUC0-8h on day 1